Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Medivation Inc    MDVN

Delayed Quote. Delayed  - 08/23 10:00:00 pm
80.27 USD   -0.19%
04:34a Dominion OK'd for 50 cent rate bump, line burials
02:44a SHAREHOLDER UPD : Brodsky & Smith, LLC Announces an Investigation of..
08/23 Pfizer's Medivation acquisition boosts Clal Biotech
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Medivation Inc : MDVN, OXBT, PTIE and SYMM added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/23/2013 | 03:30pm CEST

New York, NY - (ACCESSWIRE) - 10/23/2013 - Equity Profile Report initiates its NASDAQ Gainers Watch List adding Medivation, Inc. (NASDAQ:MDVN), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), Pain Therapeutics Inc. (NASDAQ:PTIE), and Symmetricom Inc. (NASDAQ:SYMM)

Medivation, Inc. (NASDAQ:MDVN) a biopharmaceutical company that focuses on development and commercialization of novel therapies to treat serious diseases in the United States is currently up (+8.17%) on 4,286,602 shares traded after Medivation and Astellas Announced the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer. Medivation, Inc. (NASDAQ:MDVN) is currently up (+28.65%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Medivation, Inc. (NASDAQ:MDVN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MDVN&SubId=AW

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a development stage company that engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States is currently up (+30.00%) on 6,172,456 shares traded after Oxygen Biotherapeutics Signed Agreement to Acquire Phase 3, FDA Fast Track Product to Pursue Potential $600 Million Cardiovascular Market. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) is currently up (+52.94%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=OXBT&SubId=AW

Pain Therapeutics Inc. (NASDAQ:PTIE) a biopharmaceutical company that develops novel drugs is currently up (+16.00%) on 2,154,392 shares traded after Pain Therapeutics Reported that Pfizer Elects to Continue Development of REMOXY. Pain Therapeutics Inc. (NASDAQ:PTIE) is currently up (+75.35%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Pain Therapeutics Inc. (NASDAQ:PTIE)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PTIE&SubId=AW

Symmetricom Inc. (NASDAQ:SYMM) a company that provides timekeeping technologies, instruments, and solutions worldwide is currently up (+51.15%) on 16,220,860 shares traded after Symmetricom Reported its First Quarter Fiscal Year 2014 Financial Results. Symmetricom Inc. (NASDAQ:SYMM) is currently up (+66.13%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Symmetricom Inc. (NASDAQ:SYMM)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=SYMM&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVATION INC
04:34a Dominion OK'd for 50 cent rate bump, line burials
02:44a SHAREHOLDER UPDATE : Brodsky & Smith, LLC Announces an Investigation of The Boar..
08/23 Pfizer's Medivation acquisition boosts Clal Biotech
08/23 Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale o..
08/23 Pfizer rallies 2%; buys Medivation for $14 billion
08/23 PFIZER : to acquire Medivation for $14bn
08/23 PFIZER : Market Commentary | Monday blues
08/23 PFIZER : to buy US cancer drug firm Medivation in $14bn deal
08/23 PFIZER : Monday blues
08/23 The Briefcase
More news
Sector news : Bio Therapeutic Drugs
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/17DJCourt Says Pfizer's Biosimilar of J&J's Remicade Doesn't Infringe Patent
08/16 IMS HEALTH : EU clears merger between healthcare data firms IMS and Quintiles
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/23 Who's Next After Medivation?
08/23 THE GILEAD MEDIVATION BUYOUT : What Happened?
08/23 Apple Wants You To Feel Better
08/22 Tokai Pharma in flux with lead product candidate galeterone, enrollment in mi..
08/22 Pfizer Pays Up
Advertisement
Financials ($)
Sales 2016 907 M
EBIT 2016 336 M
Net income 2016 -279 M
Finance 2016 217 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 46,64
EV / Sales 2016 14,4x
EV / Sales 2017 11,1x
Capitalization 13 319 M
More Financials
Chart MEDIVATION INC
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Full-screen chart
Technical analysis trends MEDIVATION INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 76,1 $
Spread / Average Target -5,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David T. Hung President, Chief Executive Officer & Director
Kim D. Blickenstaff Chairman
Marion McCourt Chief Operating Officer
Jennifer Jarrett Chief Financial Officer
Mohammad Hirmand Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVATION INC66.05%13 319
AMGEN, INC.7.44%130 514
GILEAD SCIENCES, INC.-19.49%107 513
CELGENE CORPORATION-4.80%88 371
REGENERON PHARMACEUTIC..-22.52%44 288
VERTEX PHARMACEUTICALS..-19.74%25 023
More Results